Brief: Mauna Kea Receives 510(k) Clearance For Cellvizio Needle-Based AQ-Flex 19 Confocal Miniprobe
Feb 25 (Reuters) - MAUNA KEA TECHNOLOGIES SAS MKEA.PA :
* MAUNA KEA TECHNOLOGIES RECEIVES 510(K) CLEARANCE FOR THE CELLVIZIO® NEEDLE-BASED AQ-FLEX™
19
CONFOCAL MINIPROBE™ ENABLING PERIPHERAL LUNG NODULE TARGETING AND IMAGING
* CELLVIZIO® AQ-FLEX PROBE IS CLEARED FOR USE WITH TRANSBRONCHIAL NEEDLES THROUGH EXISTING
BRONCHOSCOPES AND BRONCHOSCOPIC ACCESSORIES
Source text for Eikon: ID:nBw1XpTZQa
Further company coverage: MKEA.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))
Recent news on Mauna Kea Technologies SA
See all newsBrief: Mauna Kea Technologies Confirms Trajectory Toward Profitability By Year-End 2027
Brief: Mauna Kea Technologies Announces Results Of Its Combined General Meeting
French and Benelux stocks-Factors to watch 21 Nov
Brief: Mauna Kea Technologies Receives NMPA Regulatory Approval In China For Its Next-Generation Cellvizio Platform
Europe Research Roundup: Craneware, Croda, Genus